focus -WSS

focus

author：leisure time 2025-09-29 21:28:02 - browse：4668

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

The Food and Drug Administration granted conditional approval Thursday to the first gene therapy for Duchenne muscular dystrophy. Regulators restricted the treatment to younger patients, with additional data required to broaden its use.

The gene therapy, called Elevydis, is made by Sarepta Therapeutics. The company will charge $3.2 million for the treatment, making it the U.S.’s second most expensive drug, behind a recently approved gene therapy for hemophilia. CEO Doug Ingram said on a conference call the price was below what a recently published company-funded analysis found would be cost-effective.

“The approval of Elevidys is a watershed moment for the treatment of Duchenne. Elevydis is the first and only gene therapy approved for Duchenne, and this approval brings us closer to our goal of bringing forward a treatment that provides the potential to alter the trajectory of this degenerative disease,” Ingram said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Boston's new lab space is opening empty

focus

WSS

FDA advisers back CAR

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

RaDonda Vaught links Vanderbilt hospital issues to patient death

The strategy behind pharma's lawsuits over drug pricing reform

FDA advisers back CAR

Readout Newsletter: Bristol, Sangamo, Gilead, and more

knowledge

focus

hotspot

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Do masks work? RCTs can't tell us

How one medical school became remarkably diverse

EPA limits use of carcinogenic gas for sterilizing medical devices

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

The battle over the Brookhaven Landfill on Long Island

Psychedelics group wrestles with new pharma identity

How many hemophilia patients actually want gene therapy?

At least 13 dead in Texas as scorching temps continue

Ebola: Gilead Sciences antiviral shows promise as new treatment

focus

FDA advisers back CAR

Male and female sex labels in research insufficient, scientists say

RaDonda Vaught links Vanderbilt hospital issues to patient death

Why we need to separate burnout from moral injury in health care

3 hurdles to bringing medical devices to the U.S. market

The battle over the Brookhaven Landfill on Long Island

hotspot

Wikipedia

focus

explore